Advancing Cannabis Safety Assessments with New Approach Methodologies
Featuring US FDA representatives: Yitong Liu, PhD, DABT, Michael Santillo, PhD: Senior Research Chemist, Xiugong Gao, PhD: Research Biologist, Kirsten Eckstrum, PhD: Research Biologist, and Piper Hunt, PhD: Research Biologist
Following the 2018 Farm Bill’s legalization of hemp, the FDA has maintained regulatory oversight as consumer interest in hemp-derived cannabinoids like CBD continues to grow. To address emerging safety concerns such as liver and reproductive toxicity, FDA scientists are utilizing efficient New Approach Methodologies (NAMs) to study the health impacts of these substances.
Fri, Feb 27, 2026
9:30am – 12:00pm ET / 14:30 – 17:00 UTC
Zoom
Cost: Free
➡️ REGISTER